Cargando…

Diclofenac-Induced Allergic Contact Dermatitis: A Series of Four Patients

Allergic contact dermatitis is an immune-mediated antigen-specific skin reaction to an allergenic chemical that corresponds to a delayed-type hypersensitivity response (type IV reaction). Allergic contact dermatitis should be suspected when skin lesions are localized to the site of previous applicat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gulin, Sandra Jerkovic, Chiriac, Anca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120621/
https://www.ncbi.nlm.nih.gov/pubmed/27882527
http://dx.doi.org/10.1007/s40800-016-0039-3
_version_ 1782469271473881088
author Gulin, Sandra Jerkovic
Chiriac, Anca
author_facet Gulin, Sandra Jerkovic
Chiriac, Anca
author_sort Gulin, Sandra Jerkovic
collection PubMed
description Allergic contact dermatitis is an immune-mediated antigen-specific skin reaction to an allergenic chemical that corresponds to a delayed-type hypersensitivity response (type IV reaction). Allergic contact dermatitis should be suspected when skin lesions are localized to the site of previous applications of the culprit drug. Lesions appear after re-exposure in susceptible persons, with delayed onset (more than 24 h after exposure). The gold standard for diagnosis is patch (epicutaneous) testing; identification and removal of any potential causal agents is crucial. Diclofenac sodium 1% topical gel contains active (diclofenac sodium) and inactive ingredients. It is a widely used non-steroidal anti-inflammatory drug, known to cause allergic contact dermatitis, and especially photoallergic contact reactions. We present four cases of diclofenac-sodium-induced allergic contact dermatitis, diagnosed based on clinical grounds: intensively itchy eczematous lesions on the sites of drug application after several days of treatment. No allergic history and no other drug intake were reported by the patients. The application of diclofenac sodium 1% topical gel was strictly forbidden in all cases; potent topical steroids proved to be effective in all cases within 2 weeks of therapy. Patch tests were performed in all cases with European standard battery, with patients’ own diclofenac sodium 1% topical gels and with diclofenac sodium 1% in petrolatum 3 weeks after completion of local steroid therapy. Readings were done after 48 h (Day 2) and 72 h (Day 3) and proved to be positive only to patients’ diclofenac sodium 1% topical gel and diclofenac sodium 1% in petrolatum. No sun exposure was allowed during the testing, and any other treatments were forbidden.
format Online
Article
Text
id pubmed-5120621
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-51206212016-12-08 Diclofenac-Induced Allergic Contact Dermatitis: A Series of Four Patients Gulin, Sandra Jerkovic Chiriac, Anca Drug Saf Case Rep Case Series Allergic contact dermatitis is an immune-mediated antigen-specific skin reaction to an allergenic chemical that corresponds to a delayed-type hypersensitivity response (type IV reaction). Allergic contact dermatitis should be suspected when skin lesions are localized to the site of previous applications of the culprit drug. Lesions appear after re-exposure in susceptible persons, with delayed onset (more than 24 h after exposure). The gold standard for diagnosis is patch (epicutaneous) testing; identification and removal of any potential causal agents is crucial. Diclofenac sodium 1% topical gel contains active (diclofenac sodium) and inactive ingredients. It is a widely used non-steroidal anti-inflammatory drug, known to cause allergic contact dermatitis, and especially photoallergic contact reactions. We present four cases of diclofenac-sodium-induced allergic contact dermatitis, diagnosed based on clinical grounds: intensively itchy eczematous lesions on the sites of drug application after several days of treatment. No allergic history and no other drug intake were reported by the patients. The application of diclofenac sodium 1% topical gel was strictly forbidden in all cases; potent topical steroids proved to be effective in all cases within 2 weeks of therapy. Patch tests were performed in all cases with European standard battery, with patients’ own diclofenac sodium 1% topical gels and with diclofenac sodium 1% in petrolatum 3 weeks after completion of local steroid therapy. Readings were done after 48 h (Day 2) and 72 h (Day 3) and proved to be positive only to patients’ diclofenac sodium 1% topical gel and diclofenac sodium 1% in petrolatum. No sun exposure was allowed during the testing, and any other treatments were forbidden. Springer International Publishing 2016-11-23 /pmc/articles/PMC5120621/ /pubmed/27882527 http://dx.doi.org/10.1007/s40800-016-0039-3 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Case Series
Gulin, Sandra Jerkovic
Chiriac, Anca
Diclofenac-Induced Allergic Contact Dermatitis: A Series of Four Patients
title Diclofenac-Induced Allergic Contact Dermatitis: A Series of Four Patients
title_full Diclofenac-Induced Allergic Contact Dermatitis: A Series of Four Patients
title_fullStr Diclofenac-Induced Allergic Contact Dermatitis: A Series of Four Patients
title_full_unstemmed Diclofenac-Induced Allergic Contact Dermatitis: A Series of Four Patients
title_short Diclofenac-Induced Allergic Contact Dermatitis: A Series of Four Patients
title_sort diclofenac-induced allergic contact dermatitis: a series of four patients
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120621/
https://www.ncbi.nlm.nih.gov/pubmed/27882527
http://dx.doi.org/10.1007/s40800-016-0039-3
work_keys_str_mv AT gulinsandrajerkovic diclofenacinducedallergiccontactdermatitisaseriesoffourpatients
AT chiriacanca diclofenacinducedallergiccontactdermatitisaseriesoffourpatients